C07D307/04

LOW MOLECULAR WEIGHT DRY POWDER POLYMER FOR USE AS PAPER-MAKING DRY STRENGTH AGENT

The disclosure provides an associative polymer, a powder, a process for forming a paper sheet, and a process for making a powder. One or more associative polymers and one or more optional surfactants may be networked to form a wet gel and a powder may be formed from the wet gel. The associative polymer may have a weight average molecular weight of from about 10 kDa to about 2,000 kDa. A method may involve adding the powder to a cellulose fiber slurry, draining the cellulose fiber slurry to form a fiber pad, and drying the fiber pad to form a paper sheet.

REDOX POLYMERIZABLE COMPOSITION WITH PHOTOLABILE REDUCING AGENTS

Polymerizable compositions comprising a redox initiator system is disclosed. The redox initiators comprises a photolabile reducing agent, that photolyzes and initiates the redox cycle. Dental compositions comprising dental resins and the photolabile redox initiator system are also described.

Trail enhancers for the selective killing of cancer cells

The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.

Trail enhancers for the selective killing of cancer cells

The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.

Method for removing undifferentiated pluripotent stem cells
12351819 · 2025-07-08 · ·

The present invention relates to a method for removing undifferentiated embryonic stem cells. In particular, the present invention relates to a method for removing undifferentiated embryonic stem cells by using cardiac glycosides (CGs). The present invention also relates to a method for preparing differentiated cells in which undifferentiated embryonic stem cells have been removed and a method for cell therapy by using such differentiated cells.

Method for removing undifferentiated pluripotent stem cells
12351819 · 2025-07-08 · ·

The present invention relates to a method for removing undifferentiated embryonic stem cells. In particular, the present invention relates to a method for removing undifferentiated embryonic stem cells by using cardiac glycosides (CGs). The present invention also relates to a method for preparing differentiated cells in which undifferentiated embryonic stem cells have been removed and a method for cell therapy by using such differentiated cells.